Metoclopramide Noridem (Metoclopramide Hydrochloride Monohydrate)

Metoclopramide works by blocking dopamine D2 receptors in the brain’s chemoreceptor trigger zone and antagonizing serotonin 5‑HT3 receptors, while stimulating serotonin 5‑HT4 receptors in the gastrointestinal tract. This dual action speeds up gastric motility and provides anti‑emetic effects.

The dosage of Metoclopramide Noridem is determined by the prescribing clinician according to the patient’s age, weight, indication, and response to therapy. Dosing regimens may differ for intramuscular versus intravenous administration and should follow the prescriber’s instructions.

Safety data for Metoclopramide in pregnancy are limited, and the product’s pregnancy category is unknown. It should only be used if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their physician, as the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metoclopramide differs from many anti‑emetics by combining dopamine antagonism with serotonin modulation, offering both prokinetic and anti‑emetic benefits. Compared with pure 5‑HT3 antagonists, it also promotes gastric emptying, which can be advantageous in gastroparesis, but it carries a higher risk of extrapyramidal side effects.

Metoclopramide Noridem should be stored at room temperature, below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

The product is supplied as an injectable solution for intramuscular or intravenous administration. The route, injection site, and infusion rate are determined by the prescribing clinician based on the indication and patient condition.

Serious risks include tardive dyskinesia, neuroleptic malignant syndrome, severe allergic reactions, and hyperprolactinemia. Patients should be monitored for involuntary movements, high fever, muscle rigidity, rash, swelling, or hormonal disturbances, and treatment should be discontinued if these occur.

Metoclopramide is contraindicated in patients with known gastrointestinal obstruction, pheochromocytoma, or a history of hypersensitivity to the drug. Caution is advised for individuals with seizure disorders, Parkinson’s disease, or those taking interacting medications such as MAO inhibitors or antipsychotics.